There's a single number on your routine blood test that predicts your risk of dying from cancer, heart disease, and infection better than cholesterol — and an FDA-approved drug may now move it.

In this Health Longevity Secrets explainer, Robert Lufkin MD breaks down lymphopenia, the IL-15 cytokine, and ANKTIVA (nogapendekin alfa inbakicept) — the first FDA-approved IL-15 super-agonist and possibly one of the most important longevity drugs of the decade.

CHAPTERS:
00:00 — Introduction: The Blood Test Number Better Than Cholesterol
00:35 — What Is Lymphopenia and Why It Matters
01:50 — Immunosenescence: Why Your T Cells Decline After Age 20
02:30 — The Mortality Data: Three Studies on Lymphopenia
03:20 — Copenhagen Study: 63% Higher All-Cause Mortality
03:50 — Coronary Angiography Study: Hazard Ratio 1.97
04:25 — Enter IL-15: The Cytokine That Builds Killer Immune Cells
05:15 — IL-15 as a Myokine: Why Resistance Training Protects Against Cancer
06:00 — Four Hallmarks of Aging Hit By One Molecule
06:30 — ANKTIVA Explained: The IL-15 Super-Agonist
07:00 — FDA Approval, Bladder Cancer, and the Soon-Shiong Reframe
08:15 — Is ANKTIVA a Longevity Drug? The Bullish Case
09:00 — The Skeptical Case: Why We Don't Know Yet
10:15 — What You Can Do Today: Track Your Number, Raise IL-15 Naturally
11:30 — Final Take and Closing

KEY TAKEAWAYS:

• Lymphopenia (absolute lymphocyte count below 1,500/μL) predicts all-cause mortality better than cholesterol in multiple large cohort studies
• IL-15 expands NK cells and CD8+ T cells — the same cells that clear senescent "zombie" cells and patrol for cancer
• Resistance training is the single strongest known endogenous IL-15 stimulus; your muscle signals your immune system to stay young
• ANKTIVA is the first FDA-approved IL-15 super-agonist (April 2024) — currently for bladder cancer but being reframed as a lymphopenia treatment
• IL-15 hits four hallmarks of aging at once: immunosenescence, senescent cell accumulation, chronic inflammation, and sarcopenia
• Honest take: exciting hypothesis with FDA approval, but zero human longevity trials yet — watch this space

STUDIES & SOURCES MENTIONED:

• Zidar et al., JAMA Network Open 2019 — Lymphopenia and mortality in 31,178 US adults (NHANES)
• Warny et al., CMAJ 2020 — Copenhagen General Population Study, lymphopenia in 108,135 adults
• Bawamia et al., Cardiology Journal 2022 — Lymphopenia and 8-year mortality in 15,179 coronary angiography patients
• FDA approval, April 22, 2024 — Nogapendekin alfa inbakicept-pmln (ANKTIVA) for BCG-unresponsive non-muscle invasive bladder cancer

Watch the full video on YouTube: https://youtu.be/220KHIdFCwg

📖 Dr. Lufkin's book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/
📰 Substack newsletter: https://robertlufkinmd.substack.com
🌐 Website: https://robertlufkinmd.com

Enjoyed this episode? Reviews on Apple Podcasts are the #1 way to help the show grow. Tap here to leave one in 30 seconds: https://podcasts.apple.com/us/podcast/health-longevity-secrets/id1585563694

⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!

New episodes every Tuesday & Thursday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com
Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

Web: https://www.robertlufkinmd.com
YouTube: https://www.youtube.com/robertlufkinmd
X: https://x.com/robertlufkinmd
Instagram: https://www.instagram.com/robertlufkinmd/
TikTok: https://www.tiktok.com/@robertlufkin
LinkedIn: https://www.linkedin.com/in/robertlufkinmd/